SYDNEY, Australia, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced that clinical data on the Company’s lead product candidate eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism, will be presented at several industry conferences in October, November and December, 2018.

New efficacy data from TACTI-mel is expected to be presented at an oral presentation at SITC.

Conference: 15th International Congress of the Society for Melanoma Research
Dates: October 24-27, 2018
Venue: Manchester Central Convention Complex, Manchester, United Kingdom
Presentation Title: Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma
Presenter: Dr. Victoria Atkinson, Medical Oncologist, Princess Alexandra Hospital, University of Queensland, Principal Investigator TACTI-mel
   
   
Conference: World Immunotherapy Congress 2018
Dates: October 30, 2018
Venue: Basel Congress Center, Basel, Switzerland
Presentation Title: Two ACTive Immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab
Presenter: Frédéric Triebel, CSO & CMO of Immutep
   
   
Conference: Society for Immunotherapy of Cancer (SITC) Annual Meeting
Dates: November 7-11, 2018
Venue: Walter E. Convention Center, Washington, D.C.
Title: Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma
Authors: Victoria Atkinson; Frederic Triebel; Christian Mueller; Chrystelle Brignone; Melissa Eastgate; Amitesh Roy; Adnan Khattak; Andrew Haydon
Title: A multicenter, phase II study in patients with first line NSCLC, or recurrent PD-X refractory NSCLC or with recurrent HNSCC receiving Eftilagimod Alpha in combination with Pembrolizumab (TACTI-002)
Authors: Martin Forster; Frederic Triebel; Christian Mueller; Chrystelle Brignone; Tatsiana Skrahina
   
   
Conference: 4th Annual ICI Europe Summit
Dates: November 27-29, 2018
Venue: The Sofitel Berlin Kurfuerstendamm, Berlin, Germany
Presentation Title: Two ACTive Immunotherapies (TACTI): Results of Phase I Trial With Metastatic Melanoma Patients (TACTI-mel) Treated With a Soluble LAG-3 Receptor (LAG-3lg or Eftilagimod Alpha) as an Antigen Presenting (APC) Activator Combined with Pembrollzumab
Presenter: Frédéric Triebel, CSO & CMO of Immutep
   

All presentations will be made available on the Company’s website at http://www.immutep.com/investors-media/presentations.html

About Immutep

Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Further information can be found on the Company’s website www.immutep.com or by contacting:

U.S. Investors:
Jay Campbell, Vice President of Business Development and Investor Relations, Immutep Limited
+1 (917) 860-9404; jay.campbell@immutep.com

Garth Russell, LifeSci Advisors
+1 (646) 876-3613; garth@lifesciadvisors.com

Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; mgregorowski@citadelmagnus.com